Navigation Links
Eating fish associated with lower risk of dying among older adults
Date:4/1/2013

Boston, MA Older adults who have higher levels of blood omega-3 levelsfatty acids found almost exclusively in fatty fish and seafoodmay be able to lower their overall mortality risk by as much as 27% and their mortality risk from heart disease by about 35%, according to a new study from Harvard School of Public Health (HSPH) and the University of Washington. Researchers found that older adults who had the highest blood levels of the fatty acids found in fish lived, on average, 2.2 years longer than those with lower levels.

"Although eating fish has long been considered part of a healthy diet, few studies have assessed blood omega-3 levels and total deaths in older adults," said lead author Dariush Mozaffarian, associate professor in the Department of Epidemiology at HSPH. "Our findings support the importance of adequate blood omega-3 levels for cardiovascular health, and suggest that later in life these benefits could actually extend the years of remaining life."

The studythe first to look at how objectively measured blood biomarkers of fish consumption relate to total mortality and specific causes of mortality in a general populationappears online April 1, 2013 in Annals of Internal Medicine.

Previous studies have found that fish, which is rich in protein and heart-healthy fatty acids, reduces the risk of dying from heart disease. But the effect on other causes of death or on total mortality has been unclear. With this new study, the researchers sought to paint a clearer picture by examining biomarkers in the blood of adults not taking fish oil supplements, in order to provide the best assessments of the potential effects of dietary consumption of fish on multiple causes of death.

The researchers examined 16 years of data from about 2,700 U.S. adults aged 65 or older who participated in the Cardiovascular Health Study (CHS), a long-term study supported by the National Heart, Lung, and Blood Institute. Participants c
'/>"/>

Contact: Marge Dwyer
mhdwyer@hsph.harvard.edu
617-432-8416
Harvard School of Public Health
Source:Eurekalert

Page: 1 2

Related biology news :

1. Unhealthy eating can make a bad mood worse
2. Inspired by deep sea sponges: Creating flexible minerals
3. Gene discovery reveals importance of eating your greens
4. Eating junk food while pregnant may make your child a junk food addict
5. Sodium transporter appears likely target for treating salt-sensitive hypertension
6. Recreating natural complex gene regulation
7. Eating bright-colored fruits and vegetables may prevent or delay ALS
8. Scientists trick iron-eating bacteria into breathing electrons instead
9. Cheating -- and getting away with it
10. R U eating healthy 2day?
11. Treating stable flies in pastures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 2014) Scientists at The New York Stem ... closer to creating a viable cell replacement therapy ... , For the first time, NYSCF scientists ... skin samples of patients with primary progressive multiple ... to induce these stem cells into becoming oligodendrocytes, ...
(Date:7/24/2014)... Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the publication ... 3 study of Zerenex (ferric citrate), the Company,s investigational ... hyperphosphatemia in patients with end-stage renal disease (ESRD) on ... with FErric CiTrate in EsrD) was published online today ... Nephrology ( JASN ). , This ...
(Date:7/24/2014)... Scientists at The New York Stem Cell Foundation ... creating a viable cell replacement therapy for multiple ... For the first time, NYSCF scientists generated induced ... of patients with primary progressive multiple sclerosis and ... these stem cells into becoming oligodendrocytes, the myelin-forming ...
Breaking Biology News(10 mins):NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2
... DENVER (Feb. 21, 2013) A new study from the ... practices in Eurasia varied widely, with some graves lavish and ... don,t know why some of these burials were so ornate, ... modern humans in Europe by almost 10,000 years," said Julien ...
... SOLOMONS, MD (February 21, 2013)--Biologists Jackie Grebmeier and Lee Cooper ... Biological Laboratory have been visiting the chilly area north of ... but it,s only in the last few years that they ... summer was the highest ice retreat in the Arctic record, ...
... NY, February 20, 2013As the nations of the world ... in endangered sharks in early March, a team of ... the oceanic whitetip shark regularly crosses international boundaries. ... predator within their own maritime borders may therefore need ...
Cached Biology News:Early human burials varied widely but most were simple 2Early human burials varied widely but most were simple 3Biologists lead international team to track Arctic response to climate change 2New research on migratory behavior of oceanic whitetip sharks can help shape conservation strategies 2New research on migratory behavior of oceanic whitetip sharks can help shape conservation strategies 3
(Date:7/24/2014)... 24, 2014 2014 Deep Research ... is a professional and in-depth research report on ... Sulphate basic information, including its definition, classification, ... This research covers the international market analysis, including ... analysis covering macroeconomic environment & economic situation analysis, ...
(Date:7/24/2014)... WIRB-Copernicus Group ® ("WCG")™, the ... services for clinical research, announced today that it ... Richmond, VA -based Alliance Engineering, ... consulting firm in the United States ... – WCG Biosafety™ – will be able to ...
(Date:7/24/2014)... Toronto, Canada (PRWEB) July 24, 2014 ... for Optimizing Dose Escalation in First in Human Studies” ... to make better go/no-go decisions. , With increasing R&D ... market, pharmaceutical companies need to maximize the knowledge collected ... go/no-go decisions and improve success in late stage development. ...
(Date:7/24/2014)...  Spherix Incorporated (SPEX) -- an intellectual property development ... property, today announced that the Company will issue a ... on Monday, August 18, 2014 for shareholders. Management has ... Monday, August 18, 2014 to discuss the company,s progress ... Anthony Hayes . Following prepared remarks, ...
Breaking Biology Technology:Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 2Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 3Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 4WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 2WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 3Best Practices for Optimizing Dose Escalation in First in Human Studies, New Webinar August 6th Hosted by Xtalks 2Spherix Schedules Shareholder Update Call 2
... Companies Also Sign Manufacturing and Distribution Agreement, ... 15 Ranbaxy,Pharmaceuticals Inc. (RPI), a wholly ... today that it has reached several,agreements with ... capsules. The third agreement pertains to Omeprazole ...
... Symbol: MS, EDMONTON, April 15 /PRNewswire-FirstCall/ - ... the treatment of multiple sclerosis (MS), today,announced that ... data from the Company,s on-going MAESTRO-03 U.S. pivotal ... of secondary progressive MS and,recommended that the trial ...
... 15 Emisphere,Technologies, Inc. (Nasdaq: EMIS ), ... Meeting on Thursday, May 8, 2008, at the ... New Jersey. The,meeting will begin at 10:00 a.m. ... Technologies, Inc. is a biopharmaceutical company that,focuses on ...
Cached Biology Technology:Ranbaxy and AstraZeneca Reach Agreement in Esomeprazole Patent Litigation 2Ranbaxy and AstraZeneca Reach Agreement in Esomeprazole Patent Litigation 3BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board 2Emisphere Technologies To Hold Annual Stockholders Meeting on May 8, 2008 2
Human SIGIRR MAb (Clone 162201)...
... 1. 1000 V, 400 mA, 100 ... constant power modes.Single-unit increments in settings ... and recalls three protocols.Outstanding choice for ... Multiphor II or GenePhor systems. Category: ...
Mouse Serpin F1/PEDF MAb (Clone 199315)...
Mouse Nodal Affinity Purified Polyclonal Ab...
Biology Products: